Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMECwN\|A{KM7:TR?=	NGjtW2pUSU6JRWK=
IST-MEL1	MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLWTWM2OD1yLkCwNFQxPyEQvF2=	M3nRXXNCVkeHUh?=
NCI-SNU-1	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjZTHJKSzVyPUCuNFAzODdizszN	NH7qSIVUSU6JRWK=
FADU	M3rUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HnSmlEPTB;MD6wNFIxQSEQvF2=	NF;BdIlUSU6JRWK=
C32	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17iPWlEPTB;MD6wNFMxPCEQvF2=	MXPTRW5ITVJ?
D-566MG	NYHOZWF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vsdGlEPTB;MD6wNFM6KM7:TR?=	Mo\wV2FPT0WU
LXF-289	NInWR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PoNWlEPTB;MD6wNFQyQSEQvF2=	NGj4VpVUSU6JRWK=
HGC-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Hub2lEPTB;MD6wNFUyKM7:TR?=	MkXSV2FPT0WU
RPMI-7951	MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rNU2lEPTB;MD6wNFcyPyEQvF2=	MYDTRW5ITVJ?
HSC-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\wNGxtUUN3ME2wMlAxQTJ7IN88US=>	NE\KfnRUSU6JRWK=
MIA-PaCa-2	M4foU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPBTWM2OD1yLkCxNFA6KM7:TR?=	M1u2c3NCVkeHUh?=
KS-1	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jKPWlEPTB;MD6wNVM2PSEQvF2=	MmDYV2FPT0WU
CAL-51	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzxTWM2OD1yLkCxOFA2KM7:TR?=	MofZV2FPT0WU
MDA-MB-361	M2\6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknTTWM2OD1yLkCxOFk2KM7:TR?=	NWfJZndJW0GQR1XS
TI-73	NU\0WoJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnK5TWM2OD1yLkCxO\|k3KM7:TR?=	MV;TRW5ITVJ?
AGS	NGfEZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\ZTWM2OD1yLkCxPVM5KM7:TR?=	MY\TRW5ITVJ?
NCI-H460	NFPtV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HscGlEPTB;MD6wNVk4PCEQvF2=	NXHQcpd{W0GQR1XS
A204	NIPQN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjXcFlyUUN3ME2wMlAzOjR7IN88US=>	NXPsVZZwW0GQR1XS
CHL-1	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX5b3hKSzVyPUCuNFIzPTFizszN	M3rNN3NCVkeHUh?=
DU-4475	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Ty[WlEPTB;MD6wNlI3OSEQvF2=	M3;UbXNCVkeHUh?=
CGTH-W-1	NGrheYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7TTWM2OD1yLkCyN\|Q6KM7:TR?=	NXzmTlltW0GQR1XS
HCC2218	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rVWmlEPTB;MD6wNlQ6PCEQvF2=	NHW3cHhUSU6JRWK=
A2780	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlOwTWM2OD1yLkCyOVMyKM7:TR?=	M2TYNXNCVkeHUh?=
NCI-H720	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Lie2lEPTB;MD6wNlU1PiEQvF2=	NF;2bZhUSU6JRWK=
NCI-N87	NWiwPW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorCTWM2OD1yLkCyOVk{KM7:TR?=	NITHcnNUSU6JRWK=
CHP-212	NGHqNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMEK2Nlgh\|ryP	MofwV2FPT0WU
NCI-H23	NVzPRVltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEK2OlUh\|ryP	NInX[lFUSU6JRWK=
D-263MG	NGG3NYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlviTWM2OD1yLkCyO\|g3KM7:TR?=	MXXTRW5ITVJ?
ME-180	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7xcGVKSzVyPUCuNFI5QTFizszN	MWnTRW5ITVJ?
SW982	M3K0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\PTWM2OD1yLkCyPVk6KM7:TR?=	NXTvZ4VYW0GQR1XS
OE19	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLIVG53UUN3ME2wMlA{ODd5IN88US=>	MYDTRW5ITVJ?
SK-LU-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHETWM2OD1yLkCzNFgzKM7:TR?=	M17UNHNCVkeHUh?=
H4	NYqxVHNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjkZXpKSzVyPUCuNFMxQSEQvF2=	NUDEUpM{W0GQR1XS
HT-144	Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NICxc2tKSzVyPUCuNFMxQTNizszN	Ml30V2FPT0WU
SK-UT-1	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfXTWM2OD1yLkCzNVc5KM7:TR?=	NWmzVoVLW0GQR1XS
D-336MG	NX3JOXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml71TWM2OD1yLkCzN\|A6KM7:TR?=	MUHTRW5ITVJ?
MDA-MB-175-VII	M1P1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXmWZJCUUN3ME2wMlA{OzV2IN88US=>	M{fEb3NCVkeHUh?=
GAMG	M365Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HCSGlEPTB;MD6wN\|Q{PSEQvF2=	M3LybnNCVkeHUh?=
CP50-MEL-B	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf3OXlKSzVyPUCuNFM1PSEQvF2=	MUjTRW5ITVJ?
OVCAR-5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXFW4NzUUN3ME2wMlA{PDhizszN	MYjTRW5ITVJ?
SK-MES-1	M3vWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLk[WxKSzVyPUCuNFM3ODZizszN	MnjUV2FPT0WU
VM-CUB-1	NYKyZno3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnxTWM2OD1yLkCzOlU4KM7:TR?=	MYTTRW5ITVJ?
WM-115	NELGcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEO3OlIh\|ryP	NXXON3pSW0GQR1XS
DSH1	MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nHVGlEPTB;MD6wN\|gxPyEQvF2=	MVHTRW5ITVJ?
Becker	M2LjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml23TWM2OD1yLkCzPFg2KM7:TR?=	MlPPV2FPT0WU
SW962	NXi2XnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHBTWM2OD1yLkCzPVQ2KM7:TR?=	M1LQOnNCVkeHUh?=
TYK-nu	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEO5PFUh\|ryP	M1rHZ3NCVkeHUh?=
HO-1-N-1	Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnFXY5XUUN3ME2wMlA1ODJzIN88US=>	NFLGUWtUSU6JRWK=
T98G	M16yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3G3OWlEPTB;MD6wOFExOyEQvF2=	NWjReVFVW0GQR1XS
ACN	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDTTWM2OD1yLkC0NVYzKM7:TR?=	NWC3OldIW0GQR1XS
SW780	NEL6WldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXnTWM2OD1yLkC0NlA{KM7:TR?=	M1;wU3NCVkeHUh?=
Detroit562	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC5TnNKSzVyPUCuNFQzOzlizszN	M3jZTHNCVkeHUh?=
BB49-HNC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX1XXlKSzVyPUCuNFQzPDNizszN	Mn\WV2FPT0WU
HN	M{TtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMESyO\|Ih\|ryP	M3jR[HNCVkeHUh?=
H9	NUfSeY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGD4fGdKSzVyPUCuNFQ{PzFizszN	NUjqbYlWW0GQR1XS
VA-ES-BJ	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzwTWM2OD1yLkC0OFQ4KM7:TR?=	MWLTRW5ITVJ?
MEL-JUSO	M2\WZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMES0O\|Uh\|ryP	MX3TRW5ITVJ?
BT-474	NG\TbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z2OGlEPTB;MD6wOFUh\|ryP	MXPTRW5ITVJ?
CaR-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlyyTWM2OD1yLkC0OVQ6KM7:TR?=	M1TUdnNCVkeHUh?=
PSN1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTz[2hKSzVyPUCuNFQ3ODNizszN	NWW1R5ZvW0GQR1XS
KYSE-510	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPxR\|RWUUN3ME2wMlA1PjR7IN88US=>	NYXlOJVHW0GQR1XS
KP-4	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonuTWM2OD1yLkC0O\|U{KM7:TR?=	M1q2NXNCVkeHUh?=
KYSE-410	M1K2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTqUFNKSzVyPUCuNFQ4PzJizszN	M{G3RnNCVkeHUh?=
G-402	NVfHOJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMES3PFkh\|ryP	MUPTRW5ITVJ?
DOK	NIHtd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMES5NFIh\|ryP	MnPaV2FPT0WU
COR-L88	M{jEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMES5NVIh\|ryP	M1S0bHNCVkeHUh?=
SKG-IIIa	NXjRTVlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFewN2dKSzVyPUCuNFQ6QDZizszN	MnrIV2FPT0WU
AN3-CA	M3PRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TFRWlEPTB;MD6wOUDPxE1?	MYfTRW5ITVJ?
SW48	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NID3T5JKSzVyPUCuNFUxOzlizszN	NVTQeG5GW0GQR1XS
YKG-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu4dVNKSzVyPUCuNFUxPzFizszN	M{PyZ3NCVkeHUh?=
KYSE-150	NUfESnFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{GxemlEPTB;MD6wOVI{PSEQvF2=	MnTtV2FPT0WU
HuO-3N1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXXTWM2OD1yLkC1NlM4KM7:TR?=	MWjTRW5ITVJ?
LB1047-RCC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLDTWM2OD1yLkC1Nlk3KM7:TR?=	NXLnXnNIW0GQR1XS
NCI-H2030	M2C2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLwTWM2OD1yLkC1OFE1KM7:TR?=	MmnlV2FPT0WU
YH-13	NFGxfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMEW3NlIh\|ryP	NF73XodUSU6JRWK=
5637	NXni[mV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX35RoRDUUN3ME2wMlA2PzRizszN	MX7TRW5ITVJ?
LOXIMVI	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjteoxKSzVyPUCuNFU5PzJizszN	NV2xOmpOW0GQR1XS
GT3TKB	MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi2TWM2OD1yLkC1PVQzKM7:TR?=	NV7kbYlDW0GQR1XS
TCCSUP	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEW5OlQh\|ryP	NWrzVmN{W0GQR1XS
EPLC-272H	M3TKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[wTWM2OD1yLkC2NlA2KM7:TR?=	M3PURXNCVkeHUh?=
LU-99A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwME[yN\|ch\|ryP	NFnsXYFUSU6JRWK=
NCI-H1755	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmwXWxVUUN3ME2wMlA3OzRzIN88US=>	NWrCPGRTW0GQR1XS
KM12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7BSIE6UUN3ME2wMlA3OzR6IN88US=>	NVjRNIdVW0GQR1XS
SF295	NVOzfm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTRTWM2OD1yLkC2OFUzKM7:TR?=	NFK3SIJUSU6JRWK=
MZ2-MEL	NFu5UW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwME[1OVMh\|ryP	MYPTRW5ITVJ?
HEC-1	NFOxPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MliwTWM2OD1yLkC2OVg5KM7:TR?=	MnvrV2FPT0WU
SW684	NGDqNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj4TWM2OD1yLkC2OVkyKM7:TR?=	NWTVT\|RsW0GQR1XS
SF539	NYfh[nBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwME[2PFEh\|ryP	MX\TRW5ITVJ?
GMS-10	NWPVfmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\UUItZUUN3ME2wMlA3Pjl7IN88US=>	MmS5V2FPT0WU
MV-4-11	NIrDfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwME[4NFMh\|ryP	Mn;FV2FPT0WU
HT-29	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnpXpRKSzVyPUCuNFY6OTlizszN	NYGwbI9JW0GQR1XS
23132-87	NULYOJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzqTWM2OD1yLkC2PVUh\|ryP	MWLTRW5ITVJ?
SW620	NYroXoNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTkcmk6UUN3ME2wMlA4ODJ4IN88US=>	MVPTRW5ITVJ?
HCC1806	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP5TWM2OD1yLkC3NVMyKM7:TR?=	M2DOSHNCVkeHUh?=
Hs-578-T	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfhbWtKSzVyPUCuNFczODhizszN	M2jSNXNCVkeHUh?=
A2058	NEjrNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2izfWlEPTB;MD6wO\|IzQCEQvF2=	Mn7yV2FPT0WU
MEL-HO	M4jRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHBTmtiUUN3ME2wMlA4OjV3IN88US=>	M3TuR3NCVkeHUh?=
HCC2998	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzzUZJKSzVyPUCuNFc{PDdizszN	NH7TRm5USU6JRWK=
HuO9	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEe1PFkh\|ryP	M4DkdHNCVkeHUh?=
CAL-39	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEe3OlYh\|ryP	M17EWHNCVkeHUh?=
M14	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED6T4FKSzVyPUCuNFc6OTNizszN	M3;QNXNCVkeHUh?=
BFTC-909	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\GTWM2OD1yLkC3PVY6KM7:TR?=	MYrTRW5ITVJ?
TE-11	NF3iSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHOPFl5UUN3ME2wMlA4QTl4IN88US=>	M2PKNHNCVkeHUh?=
TGBC1TKB	NV;WSHlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMEiwOFMh\|ryP	NHXvNYlUSU6JRWK=
L-363	M13jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT1TWM2OD1yLkC4NlA3KM7:TR?=	MmexV2FPT0WU
A431	Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEiyNUDPxE1?	MWfTRW5ITVJ?
MKN45	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEiyNVkh\|ryP	M1nYb3NCVkeHUh?=
HT-1080	M4PJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnabXBKSzVyPUCuNFg1OzlizszN	M{L0THNCVkeHUh?=
OVCAR-8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33TOmlEPTB;MD6wPFYzOiEQvF2=	NXvEO5pFW0GQR1XS
LCLC-97TM1	MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEi3Nlgh\|ryP	NEjqOW5USU6JRWK=
M059J	NXjO[Fd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMEmwNlch\|ryP	MnntV2FPT0WU
SK-MEL-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEmwOkDPxE1?	NITScWNUSU6JRWK=
TE-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3xTWM2OD1yLkC5NlA1KM7:TR?=	MnLYV2FPT0WU
KYSE-180	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXEcXVzUUN3ME2wMlA6OjZ{IN88US=>	M4O3eHNCVkeHUh?=
D-247MG	NXq4cZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr5TWM2OD1yLkC5OFU2KM7:TR?=	M{fjUnNCVkeHUh?=
8-MG-BA	NXO2V2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPWOWFKSzVyPUCuNFk1PzJizszN	M3\0b3NCVkeHUh?=
NCI-H1792	M2jzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzzXZpKSzVyPUCuNFk3OThizszN	MnL3V2FPT0WU
MCF7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SzN2lEPTB;MD6wPVY4PyEQvF2=	M2L6UHNCVkeHUh?=
NCI-H2122	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33uSGlEPTB;MD6wPVc1PSEQvF2=	MV3TRW5ITVJ?
EFO-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:zd2lEPTB;MD6wPVk6PyEQvF2=	NXXDbmtRW0GQR1XS
LB2241-RCC	NVvkN2xST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmxS5N3UUN3ME2wMlExODV2IN88US=>	MnHGV2FPT0WU
SN12C	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nFSmlEPTB;MD6xNFExPyEQvF2=	NVHiW\|NJW0GQR1XS
A498	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXjbVR2UUN3ME2wMlExOThizszN	NGrqb\|BUSU6JRWK=
PANC-03-27	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof0TWM2OD1yLkGwNlg3KM7:TR?=	M2TISnNCVkeHUh?=
NCI-H1581	M3zqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzCdHpwUUN3ME2wMlExOjlizszN	Mn\0V2FPT0WU
U-87-MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMUCzNFch\|ryP	MY\TRW5ITVJ?
G-401	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMUCzOVMh\|ryP	Mlf2V2FPT0WU
SiHa	NV\Wb4ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHmdldKSzVyPUCuNVA1QDZizszN	MkDkV2FPT0WU
U251	NE[1W2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDES4toUUN3ME2wMlExPTJ3IN88US=>	NX:2epRQW0GQR1XS
MMAC-SF	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUC1N\|Eh\|ryP	MlP6V2FPT0WU
BB65-RCC	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPGS4V{UUN3ME2wMlExPTV2IN88US=>	NYf4T\|ZlW0GQR1XS
NKM-1	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHKVJJ7UUN3ME2wMlExPjZ4IN88US=>	M1[we3NCVkeHUh?=
HD-MY-Z	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMUC4O\|Mh\|ryP	MoPMV2FPT0WU
TGBC11TKB	NFPMd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zIZ2lEPTB;MD6xNFkxOyEQvF2=	MlvqV2FPT0WU
COLO-679	NF;5TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDSZolWUUN3ME2wMlEyOjFzIN88US=>	MWPTRW5ITVJ?
TE-8	NX7sZlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMUGyOlQh\|ryP	MmK0V2FPT0WU
SK-MEL-28	NITwRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG3TWM2OD1yLkGxN\|IyKM7:TR?=	MV\TRW5ITVJ?
SH-4	M1X1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3mTWM2OD1yLkGxN\|U3KM7:TR?=	M3nE[HNCVkeHUh?=
KALS-1	NV2wb2twT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTBWJBGUUN3ME2wMlEyOzl\|IN88US=>	MkPyV2FPT0WU
RKO	M37zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMUG3OlQh\|ryP	MYLTRW5ITVJ?
OMC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLHU2JKSzVyPUCuNVE4QTdizszN	NGPiSHZUSU6JRWK=
BT-549	M3nLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnsSYJKSzVyPUCuNVE4QTlizszN	M13sPXNCVkeHUh?=
NCI-H28	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWGzSZBDUUN3ME2wMlEyQDF5IN88US=>	NFvQXWxUSU6JRWK=
RXF393	M4fGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv6TWM2OD1yLkGxPVgzKM7:TR?=	NXXuZ\|doW0GQR1XS
COLO-829	M164OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLZTWM2OD1yLkGyNFA2KM7:TR?=	NV7mfVE2W0GQR1XS
HMV-II	M3zoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jaTGlEPTB;MD6xNlAzKM7:TR?=	NWLhXI86W0GQR1XS
SW1990	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMUKxOVch\|ryP	NHPvb4xUSU6JRWK=
NCI-H1437	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fNemlEPTB;MD6xNlE2PyEQvF2=	M{jaVnNCVkeHUh?=
SNB75	NWXXR\|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2qzWGlEPTB;MD6xNlE3QSEQvF2=	Ml2zV2FPT0WU
EW-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMUK2OlEh\|ryP	NG\0cWlUSU6JRWK=
SAS	NIX0WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMUK2PUDPxE1?	MVfTRW5ITVJ?
NCI-H1666	MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUK3O\|Qh\|ryP	M2X2UnNCVkeHUh?=
A375	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4P1R2lEPTB;MD6xNlc4QCEQvF2=	M1jMOXNCVkeHUh?=
CAMA-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTlTWM2OD1yLkGyPVI1KM7:TR?=	M1iwXnNCVkeHUh?=
HuP-T4	NW[4XGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMUK5OFMh\|ryP	MVLTRW5ITVJ?
NCI-H292	MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMUOxNUDPxE1?	M3jK[HNCVkeHUh?=
PC-14	NF3CSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XoO2lEPTB;MD6xN\|IyOSEQvF2=	MV3TRW5ITVJ?
BPH-1	NIrZ[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\uUmhXUUN3ME2wMlE{PDFizszN	M1PtdXNCVkeHUh?=
GAK	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD6TWM2OD1yLkGzOVY4KM7:TR?=	NIjDU\|dUSU6JRWK=
VMRC-RCZ	NELaVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\ITWM2OD1yLkGzO\|YzKM7:TR?=	MV3TRW5ITVJ?
SK-MEL-24	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;zN\|lwUUN3ME2wMlE{QDdizszN	NHPoXo1USU6JRWK=
LB831-BLC	NIPOWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMUO4PFMh\|ryP	MX3TRW5ITVJ?
NCI-H2452	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G4d2lEPTB;MD6xN\|k2PiEQvF2=	Mn\sV2FPT0WU
RT-112	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPuVldDUUN3ME2wMlE1ODN3IN88US=>	M2TGeHNCVkeHUh?=
GP5d	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnJeZNKSzVyPUCuNVQyODRizszN	MkSxV2FPT0WU
LC-2-ad	NFXHN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPYTWM2OD1yLkG0NVIyKM7:TR?=	NUnGVYJpW0GQR1XS
MPP-89	NXnBdGJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe4[3NKSzVyPUCuNVQyOjVizszN	NWG3dYRGW0GQR1XS
NUGC-3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK3ZVZKSzVyPUCuNVQ1PzhizszN	NVnQVGd[W0GQR1XS
GI-1	M{i4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3niWGlEPTB;MD6xOFU2QCEQvF2=	M4qxenNCVkeHUh?=
HCC1419	NX\K[4FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMUS1O\|Yh\|ryP	MnrHV2FPT0WU
SW1573	NGXVdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMUS3OVgh\|ryP	MY\TRW5ITVJ?
NCI-H2347	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG3VnhKSzVyPUCuNVQ5OzlizszN	NYHDO5c2W0GQR1XS
Mewo	M{PDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPxOlhKSzVyPUCuNVQ5QDlizszN	MX3TRW5ITVJ?
639-V	M1nC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMUWwNVMh\|ryP	NVLjSHNYW0GQR1XS
AsPC-1	NFnZcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHLeXd2UUN3ME2wMlE2OjJ3IN88US=>	NXXxUYhvW0GQR1XS
NCI-H1648	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMUWyN\|Ih\|ryP	NYrKcI1xW0GQR1XS
786-0	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMUWzPFEh\|ryP	M3qzV3NCVkeHUh?=
ETK-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;5dGlEPTB;MD6xOVkh\|ryP	NYHNWm9pW0GQR1XS
BxPC-3	M32weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUW5OlYh\|ryP	Mmf5V2FPT0WU
CAL-62	NGX3NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7ONXgzUUN3ME2wMlE3OTZ7IN88US=>	NYjxOXRWW0GQR1XS
HCC1937	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\U[GlEPTB;MD6xOlI4PSEQvF2=	MV;TRW5ITVJ?
NCI-H1299	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPxTWM2OD1yLkG2Nlg2KM7:TR?=	NGPIXVNUSU6JRWK=
SW1088	M{K5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMU[0NVMh\|ryP	MWXTRW5ITVJ?
FTC-133	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\uTWM2OD1yLkG2OVQh\|ryP	Ml\WV2FPT0WU
OC-314	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMU[2PUDPxE1?	NFj3PFJUSU6JRWK=
SCC-9	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPEXI9pUUN3ME2wMlE3PzF4IN88US=>	M{HGRnNCVkeHUh?=
HT-1376	M2P5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPDTWM2OD1yLkG2PVM3KM7:TR?=	M2jHO3NCVkeHUh?=
U-2-OS	NVr1NJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOwTWM2OD1yLkG3NVc{KM7:TR?=	MnzlV2FPT0WU
COLO-824	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TPVWlEPTB;MD6xO\|I6PCEQvF2=	NH7iVlBUSU6JRWK=
BB30-HNC	NI\sbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vpZWlEPTB;MD6xO\|M{KM7:TR?=	NXPCZZFGW0GQR1XS
NCI-H2087	M3rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMUezOlgh\|ryP	NV[ye4Q3W0GQR1XS
NCI-H2170	NWfpeI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLqTWM2OD1yLkG3OVM3KM7:TR?=	M2f5OHNCVkeHUh?=
SK-OV-3	M{PwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;xTWM2OD1yLkG3OVcyKM7:TR?=	NUjHS3FYW0GQR1XS
MZ7-mel	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HERWlEPTB;MD6xO\|Y1QSEQvF2=	NUjYdZAxW0GQR1XS
NCI-H650	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XwSWlEPTB;MD6xO\|Y5OiEQvF2=	MWHTRW5ITVJ?
KOSC-2	NETJZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnQWpdkUUN3ME2wMlE4PzN2IN88US=>	NYfnNJhUW0GQR1XS
SCC-4	M1XxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDpWoRFUUN3ME2wMlE4Pzd5IN88US=>	M2nKOnNCVkeHUh?=
MDA-MB-157	M2PSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofITWM2OD1yLkG4NFgzKM7:TR?=	MULTRW5ITVJ?
KYSE-520	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTzTWM2OD1yLkG4NkDPxE1?	NXXUOHpwW0GQR1XS
LK-2	NGjwPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknnTWM2OD1yLkG4N\|A{KM7:TR?=	NHzNOXpUSU6JRWK=
KNS-81-FD	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMUizPVQh\|ryP	NXGzcHBDW0GQR1XS
IGROV-1	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoGxTWM2OD1yLkG4OFQ{KM7:TR?=	M3jqWXNCVkeHUh?=
DEL	NWG0Z2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMUi0OUDPxE1?	NXLCN\|RzW0GQR1XS
NCI-H1395	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NET4XlFKSzVyPUCuNVg3QDJizszN	M33l[nNCVkeHUh?=
JEG-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n6b2lEPTB;MD6xPFcxPSEQvF2=	MWfTRW5ITVJ?
BCPAP	M2HTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFW4[2FKSzVyPUCuNVg5PzJizszN	M4\4TnNCVkeHUh?=
CAL-27	NUC2dGd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMUmwNlIh\|ryP	MnzJV2FPT0WU
RD	M2\OdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUmxNVMh\|ryP	NXrLS3JIW0GQR1XS
RVH-421	MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3mdG1jUUN3ME2wMlE6OTF4IN88US=>	NEHyTmxUSU6JRWK=
Capan-2	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMUmyOVYh\|ryP	M1\PZXNCVkeHUh?=
COLO-680N	M1nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX2xSHgyUUN3ME2wMlE6OzZ2IN88US=>	NIq1UnBUSU6JRWK=
NCI-H1650	M2O0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:4TY4xUUN3ME2wMlIxODV5IN88US=>	M2HE[nNCVkeHUh?=
SBC-5	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXt[G1KSzVyPUCuNlAyOThizszN	NHXnfWFUSU6JRWK=
U031	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H4bmlEPTB;MD6yNFU1PyEQvF2=	M1nVNHNCVkeHUh?=
S-117	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\ZO2lEPTB;MD6yNFU3PCEQvF2=	MoDrV2FPT0WU
DoTc2-4510	M1nqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;vOGlEPTB;MD6yNFc3QSEQvF2=	MYXTRW5ITVJ?
AM-38	M163e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMkC4OFgh\|ryP	MonuV2FPT0WU
A172	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrN[odKSzVyPUCuNlExOjJizszN	NHvMbotUSU6JRWK=
HPAF-II	M3voRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TGcmlEPTB;MD6yNVI3PCEQvF2=	MlzRV2FPT0WU
769-P	MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjLdHpKSzVyPUCuNlEzQCEQvF2=	Mlf6V2FPT0WU
MFE-280	NEjsOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLUTWM2OD1yLkKxNlk5KM7:TR?=	NXnJVo1pW0GQR1XS
TE-9	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TrRmlEPTB;MD6yNVc5PiEQvF2=	NWD6cIppW0GQR1XS
C2BBe1	M3XiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITIdFhKSzVyPUCuNlIyQSEQvF2=	M4PtR3NCVkeHUh?=
EoL-1-cell	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMkKyNFMh\|ryP	NHryfY1USU6JRWK=
G-361	M4f5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMkK2PFIh\|ryP	NF7rPHJUSU6JRWK=
KYSE-270	NV3mV4JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS0dWJKSzVyPUCuNlMxQDRizszN	NH\RbpBUSU6JRWK=
TK10	NGDWenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHxbJBtUUN3ME2wMlI{OTF5IN88US=>	M1zYVHNCVkeHUh?=
ML-2	NHu3UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7nZopKSzVyPUCuNlMyOTlizszN	NIHG[nVUSU6JRWK=
MHH-ES-1	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;sOllLUUN3ME2wMlI{PjhzIN88US=>	MlLpV2FPT0WU
BHY	NHjkXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHNNXZYUUN3ME2wMlI{PjlzIN88US=>	NUezZpFNW0GQR1XS
LS-513	NX3XWWE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMkO5OlEh\|ryP	MoXNV2FPT0WU
COLO-678	NW\GSW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnqSJRHUUN3ME2wMlI1ODR2IN88US=>	NWDYV3RkW0GQR1XS
NCI-H747	NVHnRpZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMkSxOlkh\|ryP	NIDmeHdUSU6JRWK=
K5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMkSzPEDPxE1?	MorhV2FPT0WU
OS-RC-2	M3L4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvCfW5KSzVyPUCuNlQ2ODlizszN	MYfTRW5ITVJ?
KINGS-1	M4Lvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFKwOpBKSzVyPUCuNlQ2OjlizszN	M1PtcHNCVkeHUh?=
SCC-25	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXmTWM2OD1yLkK0OVY{KM7:TR?=	NX30U3k6W0GQR1XS
CAPAN-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1myPGlEPTB;MD6yOFc5OyEQvF2=	NGLPTWxUSU6JRWK=
ESS-1	M4nme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnXTotKSzVyPUCuNlQ5ODVizszN	NI\HPVlUSU6JRWK=
TE-6	NHzSWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PkZWlEPTB;MD6yOVc2KM7:TR?=	M4jt[XNCVkeHUh?=
LB2518-MEL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLqTWM2OD1yLkK1O\|c4KM7:TR?=	NF\L[4dUSU6JRWK=
COLO-800	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjNdo1uUUN3ME2wMlI2QDF{IN88US=>	M1TqcXNCVkeHUh?=
LU-134-A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnWyTWM2OD1yLkK2NVM3KM7:TR?=	M{DaU3NCVkeHUh?=
NCI-H1155	NVS2dIQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;MVZpKSzVyPUCuNlYyPjJizszN	NGDuendUSU6JRWK=
MFM-223	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnPXo9KSzVyPUCuNlY{PjNizszN	Ml;NV2FPT0WU
HTC-C3	NX[0[mZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMk[1NFYh\|ryP	NWPI[oNCW0GQR1XS
HCT-116	M2WwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXITWM2OD1yLkK2OVk6KM7:TR?=	MlvjV2FPT0WU
Ca-Ski	NUj2V\|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPFfmJ2UUN3ME2wMlI3Pjd6IN88US=>	M1vqPXNCVkeHUh?=
SBC-1	NYHhfGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnYW5o2UUN3ME2wMlI3PzR{IN88US=>	NV\ReWx5W0GQR1XS
NB69	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWT0[FFRUUN3ME2wMlI4ODh5IN88US=>	NXLuTm9yW0GQR1XS
J82	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXv0bWo2UUN3ME2wMlI4OjZ3IN88US=>	MVvTRW5ITVJ?
U-118-MG	NE\G[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M364OGlEPTB;MD6yO\|U4QSEQvF2=	NYHzUHFSW0GQR1XS
NCI-H1355	M3XtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jRSWlEPTB;MD6yPFA4PCEQvF2=	NV\MZWw2W0GQR1XS
NCI-H1048	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMki5OVYh\|ryP	MWHTRW5ITVJ?
SW954	NGTJW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoX3TWM2OD1yLkK5NlI4KM7:TR?=	NEjJ[mlUSU6JRWK=
NMC-G1	NGfRcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\mSZBKSzVyPUCuNlkzPzdizszN	NX3PWpFTW0GQR1XS
SW1710	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[1cHNKSzVyPUCuNlk1QTRizszN	MnntV2FPT0WU
KY821	M4LIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr2OJlKSzVyPUCuNlk5PzJizszN	MmjNV2FPT0WU
HCC38	NFTPSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwM{CwO\|gh\|ryP	MXnTRW5ITVJ?
NCI-SNU-5	M{nP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfzcINKSzVyPUCuN\|A2PCEQvF2=	MVjTRW5ITVJ?
ES8	NHWzeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fkR2lEPTB;MD6zNFc5PCEQvF2=	MlvPV2FPT0WU
COLO-792	NFT1fJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HKemlEPTB;MD6zNVI2OSEQvF2=	NGfEZW5USU6JRWK=
BFTC-905	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX0TWM2OD1yLkOxOVIyKM7:TR?=	NXy0W2sxW0GQR1XS
ChaGo-K-1	NHnNW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTkWlhKSzVyPUCuN\|E4OTVizszN	MXzTRW5ITVJ?
Daoy	NEDjV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXtfHVRUUN3ME2wMlMyPzJ\|IN88US=>	MWnTRW5ITVJ?
SJSA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf1TWM2OD1yLkOxPFQ4KM7:TR?=	M33VcHNCVkeHUh?=
KNS-62	NGLoPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NED2VGNKSzVyPUCuN\|IxQDhizszN	NHXUSo5USU6JRWK=
CAKI-1	M2X5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofjTWM2OD1yLkOyNVEyKM7:TR?=	NX3DOYpMW0GQR1XS
UACC-62	NFfqOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnJ[I1KSzVyPUCuN\|IzOjdizszN	MXfTRW5ITVJ?
HuCCT1	M1;BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\uVWlEPTB;MD6zNlI5OyEQvF2=	NITuW5pUSU6JRWK=
CTB-1	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwM{K3OVMh\|ryP	Mn7GV2FPT0WU
NTERA-S-cl-D1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;1NoRKSzVyPUCuN\|I5OzZizszN	NE[wOHJUSU6JRWK=
T-24	NWXUOJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XJcWlEPTB;MD6zN\|E2QSEQvF2=	M4\BSnNCVkeHUh?=
KYSE-70	NHTEXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVW1Opd6UUN3ME2wMlM{Ojh\|IN88US=>	MXfTRW5ITVJ?
SW626	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fOT2lEPTB;MD6zN\|U{OiEQvF2=	MXrTRW5ITVJ?
LB996-RCC	NHLVWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzVZohKSzVyPUCuN\|M3OTlizszN	NWfzfGVDW0GQR1XS
DMS-273	NXvJRZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3yTFExUUN3ME2wMlM{QTF4IN88US=>	MYPTRW5ITVJ?
SW1783	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrnW3RKSzVyPUCuN\|M6QTdizszN	M3;USXNCVkeHUh?=
KU812	NYGwdWZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfkTWM2OD1yLkO0NFM5KM7:TR?=	NF\qNGlUSU6JRWK=
HSC-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjCeYtyUUN3ME2wMlM1ODV\|IN88US=>	MWPTRW5ITVJ?
A3-KAW	M3:3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwM{SxOlIh\|ryP	MVnTRW5ITVJ?
COLO-684	M2jHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwM{S1NFEh\|ryP	M4G1PHNCVkeHUh?=
NCI-H2405	NF7pRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\wTWM2OD1yLkO0OlMyKM7:TR?=	NUnldpI1W0GQR1XS
NCI-H2228	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmK2TWM2OD1yLkO1N\|U4KM7:TR?=	MlfkV2FPT0WU
NB13	NVj1Tmt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrYOVNKSzVyPUCuN\|Y5OjlizszN	M17qRnNCVkeHUh?=
no-11	M3z4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHvTWM2OD1yLkO2PVUh\|ryP	M4rWbXNCVkeHUh?=
DK-MG	NGDnOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwM{exPFgh\|ryP	NFvtTI9USU6JRWK=
NBsusSR	NYq5foFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjGS\|IyUUN3ME2wMlM4Ojh3IN88US=>	MlHtV2FPT0WU
KP-N-YS	NFPuNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjiTWM2OD1yLkO3OFY{KM7:TR?=	MoDiV2FPT0WU
CFPAC-1	M{\LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzpTWM2OD1yLkO3OVE5KM7:TR?=	M2jCdnNCVkeHUh?=
KARPAS-45	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPEcXlKSzVyPUCuN\|c5PjJizszN	M1XveXNCVkeHUh?=
NCI-H1793	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPOPWpoUUN3ME2wMlM5PTFizszN	M{f3OHNCVkeHUh?=
HCE-T	M{DoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwM{i2NFMh\|ryP	MoC0V2FPT0WU
NCI-H520	M3P4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwM{i3NFMh\|ryP	NGfRUmJUSU6JRWK=
HCC2157	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwM{i3PFEh\|ryP	MlfaV2FPT0WU
EW-18	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ewT2lEPTB;MD6zPFk1OSEQvF2=	NUnkWpV2W0GQR1XS
RO82-W-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLLb5BKSzVyPUCuN\|k3QTlizszN	NFjoWo5USU6JRWK=
HuP-T3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTkXJFrUUN3ME2wMlQxOTR\|IN88US=>	NGjmdW9USU6JRWK=
PANC-10-05	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4ra[2lEPTB;MD60NVE4KM7:TR?=	MYXTRW5ITVJ?
NCI-H1703	NXGzUI45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFi0T2dKSzVyPUCuOFE1PDZizszN	NWXlO4pZW0GQR1XS
TE-10	NELOcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzxTWM2OD1yLkSxOFQ4KM7:TR?=	NVW3WVgzW0GQR1XS
HOS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DhcGlEPTB;MD60NVY5OiEQvF2=	M4jpOXNCVkeHUh?=
LN-405	NXi2b5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;veINLUUN3ME2wMlQyPjh5IN88US=>	MUTTRW5ITVJ?
A427	NFzD[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH1TYhzUUN3ME2wMlQyQThzIN88US=>	MmT4V2FPT0WU
CAL-12T	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2ruXGlEPTB;MD60Nlc5KM7:TR?=	MXvTRW5ITVJ?
SW756	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNESxPFMh\|ryP	M2jmPXNCVkeHUh?=
YAPC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjuZpNKSzVyPUCuOFUxQCEQvF2=	NFTBW4ZUSU6JRWK=
GOTO	NUjzd2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfTZZBIUUN3ME2wMlQ2OTZizszN	NXPOXIdsW0GQR1XS
C3A	NG\LZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4S2N2lEPTB;MD60OVQ{PyEQvF2=	MY\TRW5ITVJ?
UM-UC-3	NVTGPFZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;aVmo4UUN3ME2wMlQ2PDdizszN	NYHpUJZNW0GQR1XS
NCI-H1573	M3naVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnqVWNvUUN3ME2wMlQ2PTZ7IN88US=>	M{\scnNCVkeHUh?=
LS-411N	NXXKcGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfqdYRKSzVyPUCuOFY2OjdizszN	M2TFcXNCVkeHUh?=
COR-L23	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXaUoJKSzVyPUCuOFY4PjRizszN	NE\nUVBUSU6JRWK=
HCE-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjxU2VsUUN3ME2wMlQ4PDR4IN88US=>	MnTWV2FPT0WU
NCI-H2291	NIHhdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwNEe4PVYh\|ryP	M4HpSnNCVkeHUh?=
A101D	NGPDT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETnb5ZKSzVyPUCuOFgxPTNizszN	NGfjWVJUSU6JRWK=
HT-3	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HZZWlEPTB;MD60PFIyPyEQvF2=	MYXTRW5ITVJ?
HOP-62	NYD3bZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHqy[pBKSzVyPUCuOFk5PjVizszN	M{HEPHNCVkeHUh?=
PC-3	NHfjVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrzd25KSzVyPUCuOVE2ODdizszN	MmrsV2FPT0WU
CTV-1	M2fNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDPcVVQUUN3ME2wMlUzPjZ7IN88US=>	MVvTRW5ITVJ?
PANC-08-13	M4rWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\ETWM2OD1yLkWzNVc4KM7:TR?=	MnjXV2FPT0WU
CAL-120	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\mXmlEPTB;MD61N\|M6QSEQvF2=	NIDnblJUSU6JRWK=
UMC-11	M1LaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnuVHpKSzVyPUCuOVUzOzRizszN	NWWwOZpyW0GQR1XS
MSTO-211H	NVz1TnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fF[mlEPTB;MD61OVc3OiEQvF2=	NHK2XZBUSU6JRWK=
NCI-H2126	NHPHXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LxcWlEPTB;MD61OlgyPSEQvF2=	NWL5RXdTW0GQR1XS
SNU-C2B	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4C2V2lEPTB;MD61O\|k4PyEQvF2=	MW\TRW5ITVJ?
DBTRG-05MG	NEHic4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nDbWlEPTB;MD61PFA2OyEQvF2=	M2Psc3NCVkeHUh?=
MKN1	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LRWWlEPTB;MD61PFc5OyEQvF2=	NFfjUldUSU6JRWK=
ES3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TGbWlEPTB;MD61PVEzPCEQvF2=	MUfTRW5ITVJ?
OVCAR-3	NX[3UFdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3XTWM2OD1yLkW5N\|QyKM7:TR?=	NWPkV\|k2W0GQR1XS
ACHN	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPxVm5KSzVyPUCuOlA2PjlizszN	MVTTRW5ITVJ?
SW872	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK2PXVyUUN3ME2wMlYxPzZ\|IN88US=>	M4T3VXNCVkeHUh?=
CP66-MEL	MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zEW2lEPTB;MD62NFk3QSEQvF2=	M1\OTnNCVkeHUh?=
NCI-H661	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHu3WoVKSzVyPUCuOlEyODRizszN	NYCyVXFLW0GQR1XS
UACC-893	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIn5dpNKSzVyPUCuOlM3QDFizszN	NHHYcHRUSU6JRWK=
JVM-3	NV\qd4M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Twd2lEPTB;MD62N\|gxPCEQvF2=	M3SzPXNCVkeHUh?=
SF268	NEjJOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3zSJp2UUN3ME2wMlY1OzR7IN88US=>	MVfTRW5ITVJ?
OCI-AML2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkm0TWM2OD1yLk[1N\|k4KM7:TR?=	MoHZV2FPT0WU
RPMI-8226	NH\KelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W2VGlEPTB;MD62OlMzOyEQvF2=	M3fYfHNCVkeHUh?=
MKN28	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwNk[2NlQh\|ryP	MofWV2FPT0WU
MDA-MB-453	M4TuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr0dJhkUUN3ME2wMlY4OThizszN	MV\TRW5ITVJ?
BV-173	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwNki2O\|kh\|ryP	NV\l[WlCW0GQR1XS
NCI-H358	NGLDeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ToNWlEPTB;MD62PFczPiEQvF2=	MkTIV2FPT0WU
NCI-H1651	NH;FNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DRTmlEPTB;MD63JO69VQ>?	NHXKT4NUSU6JRWK=
MDA-MB-415	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnEdnlKSzVyPUCuO\|A5OjlizszN	M3qyRnNCVkeHUh?=
8305C	M{jMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP2dJpKSzVyPUCuO\|I1QThizszN	NWfjTVFXW0GQR1XS
EFM-19	M1HHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvKT\|ZVUUN3ME2wMlc{PjdzIN88US=>	M13LdHNCVkeHUh?=
RERF-LC-MS	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwN{S2NVMh\|ryP	NEfYeZpUSU6JRWK=
A388	M4PQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXmdVBLUUN3ME2wMlc3PDZ5IN88US=>	NF72U4pUSU6JRWK=
GI-ME-N	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHxenFKSzVyPUCuO\|czOzVizszN	MULTRW5ITVJ?
IGR-1	M{PCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\kfGlEPTB;MD63PVA1OyEQvF2=	M3PCS3NCVkeHUh?=
LNCaP-Clone-FGC	NVmzWFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y0[mlEPTB;MD64NFAxPCEQvF2=	NYDsVndtW0GQR1XS
SK-MEL-3	MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS5fZZ6UUN3ME2wMlgyPTB6IN88US=>	M1rlOXNCVkeHUh?=
UACC-257	NFXISFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmq0TWM2OD1yLkiyNlMyKM7:TR?=	MnzjV2FPT0WU
OE33	M1n2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\FTWM2OD1yLki1NVAyKM7:TR?=	NVnWTIc5W0GQR1XS
QIMR-WIL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT3TWM2OD1yLki1NVQyKM7:TR?=	M3zzTHNCVkeHUh?=
NCI-H2009	NIryXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXScYRKSzVyPUCuPFU{OTFizszN	NUjiSJM{W0GQR1XS
NCI-H522	M1nFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS3bXBKSzVyPUCuPFc4QDNizszN	MXzTRW5ITVJ?
Saos-2	M1\0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PEfWlEPTB;MD64O\|g4OSEQvF2=	M1HIcXNCVkeHUh?=
NB17	M4HPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DwR2lEPTB;MD64PFAzPSEQvF2=	MlnKV2FPT0WU
D-392MG	M1voWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TD[GlEPTB;MD64PVM2PiEQvF2=	MmDSV2FPT0WU
SHP-77	NUHYW\|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwOUC0PFUh\|ryP	MVTTRW5ITVJ?
SK-MEL-30	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoC5TWM2OD1yLkmxNVg2KM7:TR?=	NGnhfYpUSU6JRWK=
GCIY	NIrneYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofMTWM2OD1yLkmxPFQ{KM7:TR?=	MnjRV2FPT0WU
HCC70	M2DsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPZTWM2OD1yLkmyNFU6KM7:TR?=	MonKV2FPT0WU
LU-65	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7MTWM2OD1yLkmyOVkyKM7:TR?=	M3vTPHNCVkeHUh?=
NCI-H1563	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PqSWlEPTB;MD65OFg3PSEQvF2=	NYfSTGozW0GQR1XS
KURAMOCHI	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTNTWM2OD1yLkm1NVkzKM7:TR?=	NFPtcWpUSU6JRWK=
PA-1	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPVdIFKSzVyPUCuPVU1OjRizszN	M3HIUnNCVkeHUh?=
NOS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvNTWM2OD1yLkm3OFg6KM7:TR?=	NGT2bIpUSU6JRWK=
NCI-H69	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Hr[WlEPTB;MD65O\|Y{PCEQvF2=	MlLSV2FPT0WU
KYSE-450	M1H0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rXNmlEPTB;MD65PFYzPiEQvF2=	M{TaT3NCVkeHUh?=
8505C	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnmZldKSzVyPUCuPVk6QDJizszN	NXnlfIh2W0GQR1XS
TGBC24TKB	M{O2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFwMECwPFQh\|ryP	M2rG[XNCVkeHUh?=
PFSK-1	NYLYTIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DaZWlEPTB;MT6wNVQzQCEQvF2=	MUHTRW5ITVJ?
EKVX	NUnZWHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwMEOxNlEh\|ryP	NVziU2tNW0GQR1XS
RCM-1	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTFwMEW1NFch\|ryP	M2Dae3NCVkeHUh?=
SW900	NWfJbZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPCTWM2OD1zLkC3PFMh\|ryP	MWjTRW5ITVJ?
D-542MG	M2XFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\TTWM2OD1zLkC3PFU2KM7:TR?=	MlP1V2FPT0WU
SK-PN-DW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXraeHJjUUN3ME2xMlExODV4IN88US=>	NGXTN5FUSU6JRWK=
NCI-H727	NUjQ[ldGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFwMUCxOVQh\|ryP	Mmj1V2FPT0WU
SW837	M1XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFwMUC5OVQh\|ryP	NYfzfVlGW0GQR1XS
BT-20	NUe3O2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\GXm1SUUN3ME2xMlEyOjB2IN88US=>	MoDlV2FPT0WU
RH-18	M2q2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\YZmlEPTB;MT6xN\|ExOyEQvF2=	NX;0SVlSW0GQR1XS
TE-12	NY\Ndoo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwMUOzN\|Mh\|ryP	M1jHNXNCVkeHUh?=
NB10	M2LZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwMUOzOFQh\|ryP	NY\EXWl{W0GQR1XS
AU565	NWnEdWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DiTGlEPTB;MT6xOVk4OyEQvF2=	MkD4V2FPT0WU
OAW-42	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTFwMUizNFYh\|ryP	M2DjVHNCVkeHUh?=
DJM-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnMTWM2OD1zLkG5PFgyKM7:TR?=	M2jNO3NCVkeHUh?=
HH	NEG4OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFwMkO4N\|Eh\|ryP	MljMV2FPT0WU
LAMA-84	M3rGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLoSphbUUN3ME2xMlI4Ozl2IN88US=>	M4DXVnNCVkeHUh?=
KNS-42	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTFwM{CyPVYh\|ryP	NVy0PZNbW0GQR1XS
NCI-H2052	M2P4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEi3VWJKSzVyPUGuN\|A2ODdizszN	NGPDZpBUSU6JRWK=
MLMA	NELMWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHEPZlKSzVyPUGuN\|I1ODdizszN	NXvuVnFFW0GQR1XS
NB12	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfxS3pKSzVyPUGuN\|U3OzZizszN	MXnTRW5ITVJ?
NCI-H1838	NU\md3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHHTWM2OD1zLkO2N\|A3KM7:TR?=	MlTMV2FPT0WU
NCI-H526	NVHnZpo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\BTWM2OD1zLkO3PFU{KM7:TR?=	Mke5V2FPT0WU
LS-123	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETHU5lKSzVyPUGuN\|kxQTRizszN	MX\TRW5ITVJ?
HDLM-2	M33XS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEm3dI9KSzVyPUGuN\|kzPzFizszN	NIXNbplUSU6JRWK=
MC-IXC	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PzdWlEPTB;MT60NlM4OSEQvF2=	NY\ldIVXW0GQR1XS
HCT-15	NInQUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj2R3hKSzVyPUGuOFMxPjhizszN	MmT2V2FPT0WU
NCI-H596	NHHwVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HyTWlEPTB;MT60OVA3OSEQvF2=	NFPX[WxUSU6JRWK=
ZR-75-30	NIHwW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTrOmkyUUN3ME2xMlQ4ODh{IN88US=>	Ml\KV2FPT0WU
A704	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjISolmUUN3ME2xMlY3PTZ\|IN88US=>	Mn7XV2FPT0WU
OVCAR-4	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDITG5{UUN3ME2xMlY6PjB5IN88US=>	Moe5V2FPT0WU
SW1417	MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1GwSGlEPTB;MT63Nlg1QSEQvF2=	Mle0V2FPT0WU
CAS-1	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\tRWlEPTB;MT63N\|k{PiEQvF2=	MX\TRW5ITVJ?
IST-SL1	NUHKTldpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfOfIpKSzVyPUGuO\|k4PTlizszN	NXznO3VqW0GQR1XS
A253	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHXcYpKSzVyPUGuPFIzOzlizszN	M{ToOnNCVkeHUh?=
EW-16	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mke3TWM2OD1zLkiyPFc2KM7:TR?=	NVq0fJpOW0GQR1XS
SK-NEP-1	NELMSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LQ[WlEPTB;MT64Olk5QCEQvF2=	M3;lTXNCVkeHUh?=
NCI-H226	NYS1c2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTFwOEmzOVkh\|ryP	Ml7zV2FPT0WU
HOP-92	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnWdpVlUUN3ME2xMlk3ODl7IN88US=>	M{XWdXNCVkeHUh?=
NCI-H441	NH\nWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vnS2lEPTB;Mj6wNlM{PyEQvF2=	NVrqS5NyW0GQR1XS
LU-139	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkGzTWM2OD1{LkCzNVE1KM7:TR?=	M1;ycXNCVkeHUh?=
SJRH30	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIW2NnlKSzVyPUKuNFQzPTNizszN	MXHTRW5ITVJ?
MG-63	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jRTGlEPTB;Mj6xOFEyOSEQvF2=	MUXTRW5ITVJ?
NH-12	M{jp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTocoZFUUN3ME2yMlE2ODB4IN88US=>	NV[4VIJWW0GQR1XS
NB7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;wU4c2UUN3ME2yMlE6Pjd\|IN88US=>	M2S4fXNCVkeHUh?=
LB771-HNC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\KUYxGUUN3ME2yMlIxPTl3IN88US=>	M4n3[nNCVkeHUh?=
HCC1569	NUjiWnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvSTWM2OD1{LkK0OVg{KM7:TR?=	MlvLV2FPT0WU
D-283MED	M3;Fc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fVPWlEPTB;Mj6yOFc5OiEQvF2=	NGDzOoFUSU6JRWK=
J-RT3-T3-5	NHzGW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXsWnFFUUN3ME2yMlI2OzVzIN88US=>	NXzJZ4p{W0GQR1XS
ATN-1	NUT1e5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf3fFJKSzVyPUKuN\|MxQDJizszN	NULLOoV2W0GQR1XS
HCC1954	NIrTdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfiU3JJUUN3ME2yMlM1PDB6IN88US=>	MmDDV2FPT0WU
SCC-15	NEOx[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnFUJlKSzVyPUKuN\|k{OTJizszN	M3TKXHNCVkeHUh?=
COLO-668	M1PXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHB[mxiUUN3ME2yMlQ{OiEQvF2=	NVvnOHdvW0GQR1XS
LB373-MEL-D	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNUYZKSzVyPUKuOVQ3PzdizszN	MoXDV2FPT0WU
no-10	M4\0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\jNYhKSzVyPUKuOVQ6PDdizszN	M2KxenNCVkeHUh?=
HT-1197	NHzmbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3z2d2lEPTB;Mj62N\|E5QCEQvF2=	MlzmV2FPT0WU
DU-145	NWHsZ3JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLaU5FuUUN3ME2yMlc6OTZ{IN88US=>	NInDV4ZUSU6JRWK=
SK-N-AS	NWPJe5VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DEUWlEPTB;Mj64OFY6OiEQvF2=	NIXW[5dUSU6JRWK=
MOLT-4	NV;ZbnljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJwOEWzNlIh\|ryP	MUXTRW5ITVJ?
EW-22	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPzcVhvUUN3ME2yMlkzQDRzIN88US=>	NX7ROWRXW0GQR1XS
DB	NF;uNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnTTWM2OD1{Lkm3O\|U6KM7:TR?=	M3PjfnNCVkeHUh?=
HL-60	NUfRXGM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;4fo9KSzVyPUOuNFQ{PzZizszN	MVLTRW5ITVJ?
SK-N-DZ	NXTMPGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvuTWM2OD1\|LkC1NFc2KM7:TR?=	M1PTTHNCVkeHUh?=
NY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fQZmlEPTB;Mz6wPFU1OiEQvF2=	Mn;qV2FPT0WU
T47D	M17zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEf6S2hKSzVyPUOuNVA2PThizszN	NHv2cHdUSU6JRWK=
NCI-H2029	NGPncW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHKXopQUUN3ME2zMlIzPDd5IN88US=>	Mm\LV2FPT0WU
KARPAS-299	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;jbWdKSzVyPUOuNlYxOjdizszN	MkfXV2FPT0WU
KM-H2	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGn0d3pKSzVyPUOuN\|A3QCEQvF2=	M2X4T3NCVkeHUh?=
CHP-134	NVLjOIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHv[41KSzVyPUOuOFc{QSEQvF2=	M3v3XHNCVkeHUh?=
22RV1	NFL0WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLzUoVbUUN3ME2zMlQ6OTZ6IN88US=>	MlfVV2FPT0WU
NB5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3mXGdpUUN3ME2zMlUxPjh7IN88US=>	NYLSdXFqW0GQR1XS
CW-2	NGP5S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD5TWM2OD1\|LkW1N\|E1KM7:TR?=	M{nwcXNCVkeHUh?=
EFO-21	NVrRXXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fBTmlEPTB;Mz61Olk1KM7:TR?=	MlnWV2FPT0WU
HuH-7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrGTWM2OD1\|LkW4OFE1KM7:TR?=	NWLiOmkxW0GQR1XS
ALL-PO	NGK4d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPm[20xUUN3ME2zMlYzOzN3IN88US=>	NH7WS5lUSU6JRWK=
EM-2	NEfwVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzJTWM2OD1\|Lk[5NFEyKM7:TR?=	MV3TRW5ITVJ?
KLE	M1H6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTNwN{OwNlkh\|ryP	NH31dHBUSU6JRWK=
NEC8	NULHc\|A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTNwOUG4NFgh\|ryP	MoniV2FPT0WU
KP-N-YN	NEP5eVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nvZWlEPTB;Mz65N\|Q4PiEQvF2=	NEnHOlRUSU6JRWK=
SK-MEL-1	M1jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DaZ2lEPTB;ND6wN\|UyQCEQvF2=	MYPTRW5ITVJ?
CAL-54	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHjUVlFUUN3ME20MlA2QTFizszN	M13r[3NCVkeHUh?=
MS-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;VUmlEPTB;ND6xOlE2PSEQvF2=	MnTzV2FPT0WU
NCI-H209	M1r0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDBTWM2OD12LkK5PVk6KM7:TR?=	MmnKV2FPT0WU
NOMO-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXJTWM2OD12LkOyNVMyKM7:TR?=	MorwV2FPT0WU
RPMI-2650	M2G0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTRwM{[zNlch\|ryP	MlnYV2FPT0WU
NCI-H810	M4H5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLFTWM2OD12LkO5O\|M3KM7:TR?=	NXLDR5N[W0GQR1XS
Ca9-22	M2PxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLUTWM2OD12LkS1OlkyKM7:TR?=	M3SwWnNCVkeHUh?=
ES4	NELleHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7md\|NKSzVyPUSuOFcxQTVizszN	NVTPc4RsW0GQR1XS
ES6	M4XrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmSxTWM2OD12LkS5OlU4KM7:TR?=	MoT5V2FPT0WU
DMS-114	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkm3TWM2OD12LkW0OlkyKM7:TR?=	M1jQe3NCVkeHUh?=
ONS-76	NFHoRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTRwNUe5OUDPxE1?	NVLpfFRKW0GQR1XS
K-562	NUTEUYRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLlOFZKSzVyPUSuO\|M5OTRizszN	M3vy[nNCVkeHUh?=
MHH-NB-11	NH\xTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fGW2lEPTB;ND63OVQ3OSEQvF2=	MmjBV2FPT0WU
Calu-3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTRwN{i1OFgh\|ryP	NETTN\|VUSU6JRWK=
HT55	M2DkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u1UmlEPTB;ND64OFU1PSEQvF2=	M2HiR3NCVkeHUh?=
SK-N-FI	NEPvZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M174N2lEPTB;ND64OVAxQSEQvF2=	MkjtV2FPT0WU
ES1	NXr5XnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:xVWlEPTB;ND64OlA2PyEQvF2=	MmPkV2FPT0WU
SF126	M4D4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVS2TmE1UUN3ME20Mlk{OTh2IN88US=>	NWPxfFFSW0GQR1XS
ES5	NELKdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NESxe\|VKSzVyPUWuNVI1OjdizszN	MlfCV2FPT0WU
LoVo	NXXvPIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjGVIYyUUN3ME21MlE2QDdzIN88US=>	M1GxO3NCVkeHUh?=
SNU-387	M3nwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTVwM{KzN\|kh\|ryP	MlntV2FPT0WU
C8166	M3X4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTVwM{[zN\|kh\|ryP	MlPUV2FPT0WU
LS-1034	NX3wNFlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3mzcGlEPTB;NT60NlMxPyEQvF2=	MUPTRW5ITVJ?
GR-ST	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4mwV2lEPTB;NT61NlIxOSEQvF2=	NWPxelNlW0GQR1XS
NCI-H1092	NIT2UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTVwN{K4OFMh\|ryP	NFXufHhUSU6JRWK=
647-V	NXru[IhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTVwN{S3NFYh\|ryP	M33qfXNCVkeHUh?=
EW-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnxR2pMUUN3ME21Mlc3PjJ5IN88US=>	NWS1OotlW0GQR1XS
KGN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vad2lEPTB;Nj6wPVkzOSEQvF2=	MnrMV2FPT0WU
D-423MG	NUfmXIlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYT1[lNYUUN3ME22MlQxOjh2IN88US=>	MoHhV2FPT0WU
ECC10	M1;2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjzVmNKSzVyPUeuNVAyODFizszN	MnjUV2FPT0WU
TE-5	M{\MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTdwNEGyPVgh\|ryP	Mn3UV2FPT0WU
P12-ICHIKAWA	M3P0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonNTWM2OD15LkS1OVI{KM7:TR?=	M4jXNHNCVkeHUh?=
NCI-H82	M3jybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f1XWlEPTB;Nz60OVcxOSEQvF2=	MXPTRW5ITVJ?
NCI-H1993	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTdwOEOwOlMh\|ryP	MV;TRW5ITVJ?
RH-1	NGLzOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fae2lEPTB;Nz64OVI1PCEQvF2=	M1S5VnNCVkeHUh?=
SW948	NWDpXnloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HnTGlEPTB;Nz65OlA1QSEQvF2=	NY\JflJsW0GQR1XS
CAL-33	M2jMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETsdZlKSzVyPUeuPVk6OzhizszN	NF;lVJhUSU6JRWK=
U-266	M1LafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XmcmlEPTB;OD6xOVc4PyEQvF2=	MUfTRW5ITVJ?
CAL-72	NYjN[YRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrHfYtKSzVyPUiuNlA{OiEQvF2=	M2rQbnNCVkeHUh?=
SNU-423	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33sSmlEPTB;OT6zOlY3PiEQvF2=	M4TMOHNCVkeHUh?=
KG-1	M2XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PQdWlEPTB;OT61PFQ2PiEQvF2=	MmfkV2FPT0WU
HCC1395	NFzxfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fWbmlEPTB;OT65NlM2OiEQvF2=	NIDZ[pFUSU6JRWK=
BE-13	NXm2cINwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LYd2lEPTB;MUCuPFg6OiEQvF2=	NHe1d5FUSU6JRWK=
MKN7	NU\BO4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrhTWM2OD1zMD65O\|Y2KM7:TR?=	MXPTRW5ITVJ?
697	NHy2W4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7HWGpKSzVyPUGxMlE1PzJizszN	MorNV2FPT0WU
LU-135	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTFzLkKzNFch\|ryP	MWnTRW5ITVJ?
ES7	M2PDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfrOng6UUN3ME2xNU4{OzF\|IN88US=>	MXXTRW5ITVJ?
SK-HEP-1	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFzLke2OFYh\|ryP	M2f1R3NCVkeHUh?=
BEN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUKzZW1WUUN3ME2xNU45PTFizszN	NH;tNYdUSU6JRWK=
NCI-H1770	M2\tVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT1TWM2OD1zMj6xNlYh\|ryP	MYrTRW5ITVJ?
SW13	M4HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTQdWtKSzVyPUGyMlE2PDFizszN	M2Pl[3NCVkeHUh?=
MZ1-PC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnsTWM2OD1zMj61OFUzKM7:TR?=	MnvNV2FPT0WU
Mo-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfBclVKSzVyPUGyMlc1OjFizszN	NGW5cYJUSU6JRWK=
HLE	NFPqcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPZTZFKSzVyPUGyMlgzOTVizszN	MVjTRW5ITVJ?
RCC10RGB	M1jNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPHclJUUUN3ME2xN{43PzFizszN	NHjNNXZUSU6JRWK=
COLO-320-HSR	NUfqXFI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTF\|LkezPFEh\|ryP	M3[y[3NCVkeHUh?=
BHT-101	M3W0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTF\|LkizOFUh\|ryP	MWnTRW5ITVJ?
OCUB-M	NYPnOmluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfBcVlTUUN3ME2xOE4yPjB{IN88US=>	MXjTRW5ITVJ?
MEG-01	NVX0NllsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPm[2tKSzVyPUG0MlM4ODhizszN	NHPuNlVUSU6JRWK=
RS4-11	M3PiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDBTXNKSzVyPUG0Mlc1OiEQvF2=	Mom5V2FPT0WU
MN-60	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGW0THJKSzVyPUG0Mlc5QTRizszN	NIS5eGtUSU6JRWK=
NCI-H1304	NF31NphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPM[Y5XUUN3ME2xOU4xPDJ3IN88US=>	MnPQV2FPT0WU
Ramos-2G6-4C10	NWCwUmI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknOTWM2OD1zNT6wOVgyKM7:TR?=	MY\TRW5ITVJ?
NCI-H2342	NFvmfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT0TWM2OD1zNT6yNFQ1KM7:TR?=	MmDMV2FPT0WU
LAN-6	NUT0U2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn2yTWM2OD1zNT60OFE1KM7:TR?=	NUn5PWRsW0GQR1XS
JVM-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF3LkW3OFgh\|ryP	NG\wRZNUSU6JRWK=
P30-OHK	NWD5OGplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrsR203UUN3ME2xOk4xPjF2IN88US=>	MmHNV2FPT0WU
C-33-A	NE\4Z21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGD5S2hKSzVyPUG2MlYzOTRizszN	NHTtXZBUSU6JRWK=
RPMI-8866	NGfjc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\HTWM2OD1zNj64OFk3KM7:TR?=	MXvTRW5ITVJ?
NCI-H630	M{nCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLjTXBKSzVyPUG2Mlg2OzdizszN	NFruZXNUSU6JRWK=
KYSE-140	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF5LkKwNlgh\|ryP	M2OyTXNCVkeHUh?=
T84	NWfqW3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTF6Lki2PVUh\|ryP	MlvQV2FPT0WU
KU-19-19	M{\XXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDreFJKSzVyPUG4Mlk3ODhizszN	NUnsbFlFW0GQR1XS
BALL-1	NUW1fWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPOZnZKSzVyPUG5MlM{QTlizszN	NGTpTG5USU6JRWK=
Calu-6	NHexfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj1OZFKSzVyPUG5MlQ6OiEQvF2=	NGHpcGNUSU6JRWK=
EGI-1	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zWZmlEPTB;MUmuOVk5KM7:TR?=	MkPFV2FPT0WU
MFH-ino	NIf1UHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTF7Lke0OVQh\|ryP	NYDDUI16W0GQR1XS
GB-1	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnSTWM2OD1{MD6zOVM2KM7:TR?=	NX\hO5ViW0GQR1XS
NCI-H1693	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjwVHFKSzVyPUKwMlY2ODVizszN	MmjFV2FPT0WU
SW1116	M2fpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEe1WFNKSzVyPUKwMlk{PjJizszN	MlvYV2FPT0WU
H-EMC-SS	NXTaVXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonuTWM2OD1{Mj6wOFUh\|ryP	MmXIV2FPT0WU
D-502MG	NGPLTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4L2fWlEPTB;MkKuPFI3OSEQvF2=	NGfPdIdUSU6JRWK=
IA-LM	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[5W2lEPTB;MkOuNlQ6OyEQvF2=	NGS4dGlUSU6JRWK=
SW1463	NXLtUmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTzTWM2OD1{Mz63PUDPxE1?	NHLvS2tUSU6JRWK=
JAR	NWG5UYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;6WGlEPTB;MkSuN\|I6OyEQvF2=	M4i1O3NCVkeHUh?=
HT	M2H0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfPcoFKSzVyPUK0MlQ4PTNizszN	NFfTO\|hUSU6JRWK=
LCLC-103H	MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj4PJlxUUN3ME2yOE45PDR7IN88US=>	NFjyS4hUSU6JRWK=
SNU-449	NFjO[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\EWXNKSzVyPUK0Mlg4PDFizszN	NEPQV5lUSU6JRWK=
KE-37	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDkTWM2OD1{NT6wPVI5KM7:TR?=	NXz3XHNKW0GQR1XS
NCI-H1623	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXRVJRKSzVyPUK3MlE{ODNizszN	NHLL[3pUSU6JRWK=
MOLT-13	M3jlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorMTWM2OD1{Nz6zOVE3KM7:TR?=	MVvTRW5ITVJ?
COLO-741	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLnTWM2OD1\|MT6zN\|M{KM7:TR?=	MVnTRW5ITVJ?
NB6	NHrZdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnUfo5KSzVyPUOyMlI5PzZizszN	MYrTRW5ITVJ?
MOLT-16	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDVcotYUUN3ME2zN{4xODV3IN88US=>	NELBU2NUSU6JRWK=
IST-MES1	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjuTWM2OD1\|ND6wOVQyKM7:TR?=	MV7TRW5ITVJ?
A4-Fuk	NF3LZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTN3LkC2OkDPxE1?	NVP3d5psW0GQR1XS
CAL-85-1	NFKyW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjFOZBDUUN3ME2zOU4zQDF5IN88US=>	NHzSdnJUSU6JRWK=
CCRF-CEM	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrMc5BRUUN3ME2zO{4yPTN4IN88US=>	NVK4[HhRW0GQR1XS
HAL-01	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPTeFduUUN3ME2zPE41QDh7IN88US=>	Mki5V2FPT0WU
HEL	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPtZlBRUUN3ME20N{4{PDB7IN88US=>	NWe3V5lXW0GQR1XS
EW-1	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XOW2lEPTB;NEOuOFc3QCEQvF2=	MXHTRW5ITVJ?
MDA-MB-231	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK5ZY5KSzVyPUS1MlEyQTlizszN	Mnu3V2FPT0WU
ABC-1	NEewSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTR4Lki1N\|gh\|ryP	M{H1[HNCVkeHUh?=
NCI-H446	NYq4TIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfGPG9PUUN3ME20PE42ODV6IN88US=>	NYDYdWh6W0GQR1XS
MHH-PREB-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rlOGlEPTB;NEmuOlAxPyEQvF2=	NW\RUmpbW0GQR1XS
DOHH-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\GUXVKSzVyPUS5MlY3PTZizszN	MXPTRW5ITVJ?
GCT	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTR7Lk[5O\|Yh\|ryP	M37kR3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)